natgillin/translations-raw huggingface dataset:
Trifluridin blev hovedsageligt elimineret ved metabolisme via TPase ved dannelse af den inaktive metabolit FTY. 
Trifluridine was mainly eliminated by metabolism via TPase to form an inactive metabolite, FTY.
Symptomerne inkluderer intense mavesmerter, som kan være forbundet med opkastning, blokeret eller delvist blokeret tarm, feber eller opsvulmning af maven. 
The signs include intense stomach or abdominal pain that can be associated with vomiting, blocked or partly blocked bowel, fever or swelling of the abdomen.
C.A. Papaellinas Ltd. Τηλ: +357 22741741 
Papaellinas Ltd. Τηλ: +357 22741741
Neutrofiler 
Neutrophils
Stigningerne i antal corpora lutea og implanterede embryoner, observeret i hunrotter ved høje doser, blev ikke anset som en negativ virkning (se pkt.4.6). 
The increases in the corpus luteum count and implanting embryo count observed in female rats at high doses were not considered adverse (see section 4.6).
Kvinder i den fertile alder skal derfor bruge meget effektive præventionsmidler, mens de tager Lonsurf og i 6 måneder efter, behandlingen er stoppet. 
Therefore, women of child-bearing potential must use highly effective contraceptive measures while taking Lonsurf and for 6 months after stopping treatment.
Efter optagelse i cancerceller fosforyleres trifluridin af thymidinkinase, som intracellulært metaboliseres yderligere til et deoxyribonukleinsyre (DNA)-substrat og inkorporeres direkte i DNA og dermed interfererer med DNA-funktionen og hindrer celleproliferation. 
Following uptake into cancer cells, trifluridine, is phosphorylated by thymidine kinase, further metabolised in cells to a deoxyribonucleic acid DNA substrate, and incorporated directly into DNA, thereby interfering with DNA function to prevent cell proliferation.
Symptomerne inkluderer usædvanlige blå mærker eller blødning (se punkt 2). 
The signs include unusual bruising or bleeding (see section 2).
• ondt i halsen, hæs stemme, problemer med din stemme 
• sore throat, hoarse voice, problems with your voice
Der er rapporteret alvorlige infektioner efter behandling med Lonsurf (se pkt. 
Serious infections have been reported following treatment with Lonsurf (see section 4.8).
Amning bør afbrydes under behandling med Lonsurf. 
Breast-feeding should be discontinued during treatment with Lonsurf.
• følelse af, at alting snurrer rundt (vertigo) 
• feeling of spinning (vertigo)
Det gennemsnitlige relative forhold mellem AUC hos patienter med let (n = 38) og moderat (n = 16) nedsat nyrefunktion sammenlignet med patienter med normal nyrefunktion (n = 84) var henholdsvis 1,31 og 1,43 for trifluridin og 1,34 og 1,65 for tipiracilhydrochlorid. 
The mean relative ratio of AUC in patients with mild (n=38) and moderate (n=16) renal impairment compared to patients with normal renal function (n=84) were 1.31 and 1.43 for trifluridine, respectively, and 1.34 and 1.65 for tipiracil hydrochloride, respectively.
En højere eksponering af Lonsurf blev observeret ved moderat nedsat nyrefunktion (CrCl = 30 til 59 ml /min). 
A higher exposure of Lonsurf was observed in moderate renal impairment (CrCl = 30 to 59 mL/min).
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/16/1096/001-006 
MARKETING AUTHORISATION NUMBER(S) EU/1/16/1096/001-006
Lonsurfs kliniske effekt og sikkerhed blev evalueret i et internationalt, randomiseret, dobbeltblindt placebo-kontrolleret fase III-studie (RECOURSE) hos patienter, som tidligere var behandlet for metastatisk kolorektal cancer. 
The clinical efficacy and safety of Lonsurf were evaluated in an international, randomised, doubleblind, placebo-controlled Phase III study (RECOURSE) in patients with previously treated metastatic colorectal cancer.
• Hvis du har glemt at tage en dosis, skal du tale med din læge eller apotekspersonalet. 
• If you forget a dose, talk to your doctor or pharmacist.
Trifluridin nedbrydes imidlertid hurtigt af TPase og metaboliseres hurtigt efter oral administration ved en first-pass effekt, hvorfor TPase-hæmmeren, tipiracilhydrochlorid, er tilsat. 
However, trifluridine is rapidly degraded by TPase and readily metabolised by a first-pass effect following oral administration, hence the inclusion of the TPase inhibitor, tipiracil hydrochloride.
Det er derfor ikke sandsynligt, at det i de anbefalede doser forårsager interaktion med andre lægemidler på grund af hæmning af OCT2 eller MATE1. 
Thus it is unlikely to cause an interaction with other medicinal products, at recommended doses, due to inhibition of OCT2 and MATE1.
Lonsurf forårsagede en stigning i forekomsten af gastrointestinal toksicitet, herunder kvalme, opkastning og diarré. 
Lonsurf caused an increase in the incidence of gastrointestinal toxicities including nausea, vomiting and diarrhoea.
• øget niveau af lactatdehydrogenase i blodet 
• increased lactate dehydrogenase level in your blood
Menstruationsforstyrrelser 
Menstrual disorder
Baseret på en farmakokinetisk populationsanalyse var leverfunktionsparametrene, herunder alkalisk fosfatase (ALP, 36-2.322 E/l), aspartataminotransferase (ASAT, 11-197 E/l), alaninaminotransferase (ALAT, 5-182 E/ l) og total-bilirubin (0,17-3,20 mg /dl), ikke signifikante kovariater for de farmakokinetiske parametre hverken for trifluridin eller tipiracilhydrochlorid. 
Based on the population PK analysis, liver function parameters including alkaline phosphatase (ALP, 36-2322 U/L), aspartate aminotransferase (AST, 11-197 U/L), alanine aminotransferase (ALT, 5-182 U/L) , and total bilirubin (0.17-3.20 mg/dL) were not significant covariates for PK parameters of either trifluridine or tipiracil hydrochloride.
• lavt indhold af fosfater, natrium, kalium eller calcium i blodet 
• low levels of phosphates, sodium, potassium or calcium in your blood
I de kliniske fase III-studier forekom behandlingsrelaterede infektioner oftere hos Lonsurf-behandlede patienter (5,8 %) end hos patienter i placebo-gruppen (1,8 %). 
In the Phase III clinical trials, treatment-related infections occurred more frequently in Lonsurf-treated patients (5.8%) compared to those receiving placebo (1.8%).
Den anbefalede startdosis af Lonsurf hos voksne er 35 mg/m dagligt på dag 1 til 5 og dag 8 til 12 i hver 28-dages-cyklus, så længe der observeres behandlingsmæssige fordele eller indtil uacceptabel toksicitet (se pkt. 
The recommended starting dose of Lonsurf in adults is 35 mg/m2/dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 28-day cycle as long as benefit is observed or until unacceptable toxicity occurs (see section 4.4).
Urinvejsinfektion Gingivitis 
Urinary tract infection Gingivitis
• synsproblemer som sløret syn, dobbeltsyn, nedsat syn, grå stær 
• vision troubles as blurred vision, double vision, decreased vision, cataracts
De gennemsnitlige halveringstider af tipiracilhydrochlorid på henholdsvis dag 1 og dag 12 i cyklus 1 var 2,1 timer og 2,4 timer. 
The mean t1/2 values for tipiracil hydrochloride on Day 1 of Cycle 1 and on Day 12 of Cycle 1 were 2.1 hours and 2.4 hours, respectively.
Tabel 1 - Beregning af startdosis ud fra kroppens overfladeareal (BSA) 
Table 1 - Starting dose calculation according to body surface area (BSA)
• smerte eller ubehag i dine arme eller ben 
• pain or discomfort in your arms or legs
Dosis i mg (2x dagligt) 
Dose in mg (2x daily)
61 % (N = 485) af alle randomiserede patienter fik fluorpyrimidin, som en del af deres sidste behandlingsregime før randomisering, hvor (94 %) var refraktære overfor fluorpyrimidin på dette tidspunkt. 
Sixty one percent (61%, N = 485) of all randomised patients received a fluoropyrimidine as part of their last treatment regimen prior to randomisation, of which 455 (94%) were refractory to the fluoropyrimidine at that time.
Det Europæiske lægemiddelagentur har dispenseret fra kravet om at fremlægge resultaterne af studier med Lonsurf i alle undergrupper af den pædiatriske population ved refraktær metastatisk kolorektal cancer og ved refraktær metastatisk gastrisk cancer (se pkt. 
The European Medicines Agency has waived the obligation to submit the results of studies with Lonsurf in all subsets of the paediatric population in refractory metastatic colorectal cancer and in refractory metastatic gastric cancer (see section 4.2 for information on paediatric use).
Træthed, svimmelhed og utilpashed kan forekomme under behandlingen (se pkt. 
Fatigue, dizziness or malaise may occur during treatment (see section 4.8).
De hyppigst observerede bivirkninger (≥ 30 %) hos patienter i behandling med Lonsurf er neutropeni (53 % [34 % ≥ grad 3]), kvalme (34 % [1 % ≥ grad 3]), træthed (32 % [4 % ≥ grad 3]), anæmi (32 % [12 % ≥ grad 3]). 
The most frequently observed adverse drug reactions (≥ 30%) in patients receiving Lonsurf are neutropenia (53% [34% ≥ Grade 3]), nausea (34% [1% ≥ Grade 3]), fatigue (32% [4% ≥ Grade 3]), anaemia (32% [12% ≥ Grade 3]).
I de farmakokinetiske analyser efter multipel administrationen af Lonsurf (35 mg/m dagligt med 5 dages behandling og 2 dages pause i 2 uger, efterfulgt af 14 dages pause og gentaget hver 4. uge), var arealet under koncentration-tid-kurven fra tid 0 til den sidste målbare koncentration (AUC0-sidste) for trifluridin ca. 3 gange højere, og maksimumkoncentrationen (Cmax) var cirka 2 gange højere efter administration af multiple doser (dag 12 i cyklus 1) af Lonsurf end efter en enkelt dosis (dag 1 i cyklus 1). 
In the pharmacokinetic (PK) analyses of the multiple dose administration of Lonsurf (35 mg/m2/dose, twice daily for 5 days a week with 2 days rest for 2 weeks followed by a 14-day rest, repeated every 4 weeks), trifluridine area under the concentration-time curve from time 0 to the last measurable concentration (AUC0-last) was approximately 3-fold higher and maximum concentration (Cmax) was approximately 2-fold higher after multiple dose administration (Day 12 of Cycle 1) of Lonsurf than after single-dose (Day 1 of Cycle 1).
Bidrag fra tipiracilhydrochlorid 
Contribution of tipiracil hydrochloride
• højt blodsukker (hyperglykæmi), øget indhold af natrium, urinstof, kreatinin og kalium i blodet 
• high blood sugar (hyperglycaemia), increased salt, urea, creatinine and potassium in your blood
Som følge af neutropeni kan der opstå feber (febril neutropeni) og infektion i blodet (septisk shock) 
(febrile neutropenia) and blood infection (septic shock) may occur
• virusinfektion 
• viral infection
Lonsurf er indiceret som monoterapi til behandling af metastatisk kolorektal cancer hos voksne patienter, som tidligere er blevet behandlet med, eller som ikke anses som kandidater til, tilgængelige behandlinger, herunder fluorpyrimidin-, oxaliplatin- og irinotecan-baseret kemoterapi, anti-VEGFmidler, og anti-EGFR-midler. 
Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.
Tabel 5 - Bivirkninger rapporteret i kliniske studier hos patienter behandlet med Lonsurf Systemorganklasse (MedDRA) 
Table 5 - Adverse drug reactions reported in clinical trials in patients treated with Lonsurf System Organ Class (MedDRA)a
Der blev udført en toksikologisk vurdering af trifluridin/tipiracilhydrochlorid hos rotter, hunde og aber. 
Toxicology assessment of trifluridine/tipiracil hydrochloride was performed in rats, dogs and monkeys.
Udslæt Alopeci Pruritus Tør hud 
Rash Alopecia Pruritus Dry skin
Anbefalede dosis modifikationer 
Recommended dose adjustments
Lonsurfs overlevelsesfordel blev opretholdt efter justering for alle væsentlige prognostiske faktorer, tid siden diagnosticering af den første metastase, ECOG-PS og antal metastatiske steder (hazard ratio: 0,69; 95 % CI [0,58 til 0,81]). 
The Lonsurf survival benefit was maintained after adjusting for all significant prognostic factors, namely, time since diagnosis of first metastasis, ECOG PS and number of metastatic sites (hazard ratio: 0.69; 95% CI [0.58 to 0.81]).
Tipiracilhydrochlorid var en hæmmer af OCT2 og MATE1 in vitro, men ved koncentrationer væsentligt højere end human plasmaCmax ved steady state. 
Tipiracil hydrochloride was an inhibitor of OCT2 and MATE1 in vitro, but at concentrations substantially higher than human plasma Cmax at steady state.
0,0003 (1-sidet), 0,0006 (2-sidet) 
0.0003 (1-sided), 0.0006 (2-sided)
Hvis ovenstående gælder for dig (eller hvis du er i tvivl), så tal med din læge eller apotekspersonalet, før du tager Lonsurf. 
If the above applies to you (or you are not sure), talk to your doctor or pharmacist before taking Lonsurf.
• hævet kløende udslæt, rød hud, blister, huden falder af, nældefeber, acne 
• raised itchy rash, red skin, blisters, skin sloughing off, hives, acne
De alvorligste observerede bivirkninger hos patienter, der fik Lonsurf, er knoglemarvssuppression og gastrointestinal toksicitet (se pkt. 
The most serious observed adverse drug reactions in patients receiving Lonsurf are bone marrow suppression and gastrointestinal toxicity (see section 4.4).
Vertigo Ubehag i øret 
Vertigo Ear discomfort
Brug af anden medicin sammen med Lonsurf 
Other medicines and Lonsurf
Lonsurf består af en antineoplastisk thymidin-baseret nukleosidanalog, trifluridin, og thymidinfosforylase- (TPase-) hæmmeren tipiracilhydrochlorid i et molforhold 1:0,5 (vægtforhold, 
Lonsurf is comprised of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride, at a molar ratio 1:0.5 (weight ratio,
Ved en total daglig dosis på 50 mg skal patienten tage en 20 mg/8,19 mg tablet om morgenen og to 15 mg/6,14 mg tabletter om aftenen. 
50a a At a total daily dose of 50 mg, patients should take 1 x 20 mg/8.19 mg tablet in the morning and 2 x 15 mg/6.14 mg tablets in the evening.
In vitro evaluering af trifluridin og tipiracilhydrochlorid blev udført under anvendelse af humane optagelses- og effluxtransportører (trifluridin med MDR1, OATP1B1, OATP1B3 og BCRP; tipiracilhydrochlorid med OAT1, OAT3, OCT2, MATE1, MDR1 og BCRP). 
In vitro evaluation of trifluridine and tipiracil hydrochloride was conducted using human uptake and efflux transporters (trifluridine with MDR1, OATP1B1, OATP1B3 and BCRP; tipiracil hydrochloride with OAT1, OAT3, OCT2, MATE1, MDR1 and BCRP).
ORR (komplet respons + partielt respons) var ikke signifikant højere hos patienter, som blev behandlet med Lonsurf (4,5 % versus 2,1 %, p-værdi = 0,2833), men DCR (komplet respons, partielt respons eller stabil sygdom) var signifikant højere hos patienter, som blev behandlet med Lonsurf (44,1 % versus 14,5 %, p < 0,0001). 
The ORR (complete response + partial response) was not significantly higher in patients treated with Lonsurf (4.5% vs 2.1 %, p-value = 0.2833) but the DCR (complete response or partial response or stable disease) was significantly higher in patients treated with Lonsurf (44.1% vs 14.5%, p < 0.0001).
40 filmovertrukne tabletter 
40 film-coated tablets
I RECOURSE var der en lidt højere samlet forekomst af hæmatologiske og myelosuppressionsrelaterede bivirkninger hos patienter, der tidligere havde fået strålebehandling, sammenlignet med patienter uden forudgående strålebehandling (henholdsvis 54,6 % versus 49,2 %,), hvor det skal bemærkes, at febril neutropeni var hyppigere hos Lonsurf-behandlede patienter, som tidligere havde fået strålebehandling, end hos patienter, som ikke havde. 
There was a slightly higher incidence of overall haematological and myelosuppression-related adverse reactions for patients who received prior radiotherapy compared to patients without prior radiotherapy in RECOURSE (54.6% versus 49.2%, respectively), of note febrile neutropenia was higher in Lonsurf-treated patients who received prior radiotherapy vs. those that did not.
Pancytopeni Granulocytopeni Monocytopeni Erytropeni Leukocytose Monocytose 
Pancytopenia Granulocytopenia Monocytopenia Erythropenia Leukocytosis Monocytosis
• besvimelse (synkope) 
• passing out (syncope)
Absorberet trifluridin blev metaboliseret og udskilt i urinen som FTY og trifluridinglukuronidisomere. 
The absorbed trifluridine was metabolised, and excreted into urine as FTY and trifluridine glucuronide isomers.
Cirka halvdelen (55,4 %) af patienterne havde tidligere fået behandling med irinotecan, 33,3 % havde tidligere fået behandling med ramucisumab og 16,6 % havde tidligere fået HER2-målrettet behandling. 
Approximately half (55.4%) of patients received prior irinotecan, 33.3% received prior ramucirumab, and 16.6% received prior HER2-targeted therapy.
Hos de 800 randomiserede patienter var medianalderen 63 år, 61 % var mænd, 58 % var kaukasere/hvide, 35 % var asiater/orientalske, og 1 % var sorte/afroamerikanere, og alle patienter havde Eastern Cooperative Oncology Group (ECOG) performance status (PS) på 0 eller 1 ved baseline. 
Of the 800 randomised patients, the median age was 63 years, 61% were male, 58% were Caucasian/White, 35% were Asian/Oriental, and 1% were Black/African American, and all patients had baseline Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.
Baseret på den farmakokinetiske populationsanalyse var der ingen klinisk relevant effekt af alder, køn eller race på trifluridins og tipiracilhydrochlorids farmakokinetik. 
Based on the population PK analysis, there is no clinically relevant effect of age, gender or race on the PK of trifluridine or tipiracil hydrochloride.
• øget antal hvide blodlegemer 
• increased white blood cells
Lonsurf forårsagede en stigning i forekomsten af myelosuppression, herunder anæmi, neutropeni, leukopeni og trombocytopeni. 
Lonsurf caused an increase in the incidence of myelosuppression including anaemia, neutropenia, leukopenia, and thrombocytopenia.
De bivirkninger, som hyppigst (≥ 2 %) resulterede i seponering af Lonsurf, dosisreduktion, dosisudskydelse, eller doseringsafbrydelse, var neutropeni, anæmi, leukopeni, træthed, trombocytopeni, kvalme og diarré. 
The most common adverse drug reactions (≥ 2%) in patients receiving Lonsurf that resulted in treatment discontinuation, dose reduction, dose delay, or dose interruption were neutropenia, anaemia, leukopenia, fatigue, thrombocytopenia, nausea and diarrhoea.
OS- og PFS-fordelen blev observeret i alle relevante præspecificerede undergrupper, herunder race, geografisk område, alder (< 65; ≥ 65), køn, ECOG-PS, KRAS-status, tid siden diagnosticering af den første metastase, antal metastatiske steder og fokus for primær tumor. 
The OS and PFS benefit was observed consistently, in all relevant pre-specified subgroups, including race, geographic region, age (< 65; ≥ 65), sex, ECOG PS, KRAS status, time since diagnosis of first metastasis, number of metastatic sites, and primary tumour site.
• hævede slimhinder - det kan være i næsen, munden, halsen, øjnene, vagina, lunger eller tarme 
• swelling of mucous membranes - this could be inside the nose, mouth, throat, eyes, vagina, lungs or gut
Tabel 3 - Anbefalede dosisjusteringer for Lonsurf ved hæmatologiske og ikke-hæmatologiske bivirkninger 
Table 3 - Recommended dose modifications for Lonsurf in case of haematological and non-haematological adverse reactions
Almindelig: Kan forekomme hos op til 1 ud af 10 personer 
Common: may affect up to 1 in 10 people:
Næsten alle (99,8 %) patienter havde tidligere fået behandling med fluorpyrimidin, 100 % havde tidligere fået behandling med platin og 90,5 % havde tidligere fået behandling med taxan. 
Nearly all (99.8%) patients received prior fluoropyrimidine, 100% received prior platinum therapy and 90.5% received prior taxane therapy.
• du har nyreproblemer 
• you have kidney problems
Resultater af dyrestudier indikerede ikke indvirkning af trifluridin og tipiracilhydrochlorid på hanlig og hunlig fertilitet hos rotter. 
Results of animal studies did not indicate an effect of trifluridine and tipiracil hydrochloride on male and female fertility in rats.
• Øvrige indholdsstoffer er: - Tabletkerne: Lactosemonohydrat, pregelatineret stivelse (majs) og stearinsyre. 
• The other ingredients are: - Tablet core: lactose monohydrate, starch pregelatinised (Maize) and stearic acid.
• blodpropper, f.eks. i hjernen eller benene 
• blood clots, e.g. in the brain or legs
Kriterierne for doseringsgenoptagelse er gældende for alle patienter ved starten af næste cyklus, uanset om kriterierne for doseringsafbrydelse blev mødt eller ej. 
≥ 75 × 109/L a Resumption criteria applied to the start of the next cycle for all patients regardless of whether or not the interruption criteria were met.
Periodontal sygdom Tandlidelse 
Periodontal disease Tooth disorder
Lonsurf er indiceret som monoterapi til behandling af metastatisk gastrisk cancer hos voksne patienter, herunder adenokarcinom i den gastroøsofageale overgang, som tidligere er blevet behandlet med mindst to forudgående systemiske behandlingsregimer for fremskreden sygdom (se pkt. 
Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease (see section 5.1).
• Uge 1 - tag dosis 2 gange daglig i 5 dage - derefter 2 dage uden medicin 
• Week 1 - take the dose 2 times a day for 5 days - then have 2 days off - no medicine
Dyrestudier har vist, at trifluridin, tipiracilhydrochlorid og/eller deres metabolitter udskilles i mælk (se pkt. 
Studies in animals have shown excretion of trifluridine, tipiracil hydrochloride and/or their metabolites in milk (see section 5.3).
Angst Insomni 
Anxiety Insomnia
Lonsurfs kliniske effekt og sikkerhed blev evalueret i et internationalt, randomiseret, dobbeltblindt, placebokontrolleret fase III-studie (TAGS) hos patienter, som tidligere var behandlet for metastatisk gastrisk cancer (herunder adenokarcinom i den gastroøsofageale overgang), og som tidligere var blevet behandlet med mindst to forudgående systemiske behandlingsregimer for fremskreden sygdom, herunder fluorpyrimidin-, platin- og enten taxan- eller irinotecan-baseret kemoterapi samt, hvis relevant, human epidermal vækstfaktor-receptor 2 (HER2)-målrettet behandling. 
The clinical efficacy and safety of Lonsurf were evaluated in an international, randomised, doubleblind, placebo-controlled Phase III study (TAGS) in patients with previously treated metastatic gastric cancer (including adenocarcinoma of the gastroesophageal junction), who had been previously treated with at least two prior systemic treatment regimens for advanced disease, including fluoropyrimidine-, platinum-, and either taxane- or irinotecan-based chemotherapy, plus if appropriate human epidermal growth factor receptor 2 (HER2) -targeted therapy.
Det primære effektmål var samlet overlevelse (overall survival, OS), og støttende effektmål var progressionsfri overlevelse (progression-free survival, PFS), samlet responsrate (overall response rate, ORR) og sygdomskontrolrate (disease control rate, DCR). 
The primary efficacy endpoint was overall survival (OS), and supportive efficacy endpoints were progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR).
Patienter på 65 år og ældre, som fik Lonsurf, havde, sammenlignet med patienter under 65 år, en højere incidens af følgende bivirkninger: - metastatisk kolorektal cancer (RECOURSE): Grad 3 og 4 neutropeni (48 % versus 30 %), grad 3 anæmi (26 % versus 12 %), grad 3 og 4 leukopeni (26 % versus 18 %) og grad 3 og 4 trombocytopeni (9 % versus 2 %), - metastatisk gastrisk cancer (TAGS): Grad 3 og 4 nedsat neutrofiltal (17,0 % versus 6,6 %), nedsat appetit (37,3 % versus 31,9 %), asteni (22,2 % versus 17,0 %) og stomatitis (7,2 % versus 2,2 %). 
Patients 65 years of age or older who received Lonsurf had a higher incidence of the following events compared to patients younger than 65 years: - metastatic colorectal cancer (RECOURSE): Grade 3 or 4 neutropenia (48% vs 30%), Grade 3 anaemia (26% vs 12%), Grade 3 or 4 leukopenia (26% vs 18%) and Grade 3 or 4 thrombocytopenia (9% vs 2%), - metastatic gastric cancer (TAGS): Grade 3 or 4 neutrophil count decrease (17.0% vs 6.6%), decreased appetite (37.3% vs 31.9%), asthenia (22.2% vs 17.0%) and stomatitis (7.2% vs 2.2%).